Sankey It
Loading...
Pfizer Inc. FY2023 income statement | Sankey It
Sankey It · PFE
Pfizer Inc. FY2023 income statement
USD · fiscal year ended 2023-12-31
FY2025
FY2024
FY2023
FY2022
FY2021
Quarterly
Annual
comfortable
compact
Hide amounts
Export
Fullscreen
Pfizer Inc. FY2023 income statement
Flow diagram with 9 nodes and 8 flows for Pfizer Inc. FY2023 income statement. Values: Biopharma Segment US$57.2B, Business Innovation Segment US$1.3B, Revenue US$59.6B, Cost of Revenue US$29.2B, Gross Profit US$30.3B, Operating Expenses US$25B, Operating Income US$5.3B, Other Expense US$4.2B, Net Income US$2.1B.
Biopharma Segment
US$57.2B
-42% Y/Y
96% of revenue
Business Innovation Segment
US$1.3B
2% of revenue
Revenue
US$59.6B
-41% Y/Y
Cost of Revenue
(US$29.2B)
-24% Y/Y
49% of revenue
Gross Profit
US$30.3B
-51% Y/Y
51% margin
Operating Expenses
(US$25B)
+2% Y/Y
42% of revenue
Operating Income
US$5.3B
-86% Y/Y
9% margin
Other Expense
(US$4.2B)
+50% Y/Y
7% of revenue
Net Income
US$2.1B
-93% Y/Y
4% margin
Net / profit
Inputs
Tax / cost
Copy link
Share on X
Open full screen